. | Risk of LEAD . | P value . |
---|---|---|
C-statistic (95% CI) for model 2 | 0.753 (0.688–0.817) | |
Change in C-statistic (95% CI) for model 2 + TNFR1 | 0.036 (0.013–0.059) | 0.002 |
Change in C-statistic (95% CI) for model 2 + IMA | 0.007 (−0.009 to 0.022) | 0.38 |
IDI (95% CI) for TNFR1 | 0.012 (0.005–0.022) | <0.001 |
Continuous NRI (95% CI) for TNFR1 | 0.583 (0.294–0.847) | <0.001 |
Categorical NRI (95% CI) for TNFR1 | 0.171 (0.027–0.317) | 0.02 |
IDI (95% CI) for IMA | 0.001 (−0.006 to 0.009) | 0.63 |
Continuous NRI (95% CI) for IMA | 0.239 (−0.043 to 0.508) | 0.11 |
Categorical NRI (95% CI) for IMA | 0.055 (−0.021 to 0.134) | 0.18 |
. | Risk of LEAD . | P value . |
---|---|---|
C-statistic (95% CI) for model 2 | 0.753 (0.688–0.817) | |
Change in C-statistic (95% CI) for model 2 + TNFR1 | 0.036 (0.013–0.059) | 0.002 |
Change in C-statistic (95% CI) for model 2 + IMA | 0.007 (−0.009 to 0.022) | 0.38 |
IDI (95% CI) for TNFR1 | 0.012 (0.005–0.022) | <0.001 |
Continuous NRI (95% CI) for TNFR1 | 0.583 (0.294–0.847) | <0.001 |
Categorical NRI (95% CI) for TNFR1 | 0.171 (0.027–0.317) | 0.02 |
IDI (95% CI) for IMA | 0.001 (−0.006 to 0.009) | 0.63 |
Continuous NRI (95% CI) for IMA | 0.239 (−0.043 to 0.508) | 0.11 |
Categorical NRI (95% CI) for IMA | 0.055 (−0.021 to 0.134) | 0.18 |
IDI and continuous and categorical (5% and 10% risk thresholds) NRI tests were performed for model 2 plus baseline plasma concentrations of TNFR1 or IMA compared with model 2 alone. Model 2: age; sex; BMI; duration of diabetes; HbA1c; systolic and diastolic blood pressure; urinary ACR; eGFR; diabetic retinopathy stages; plasma concentrations of total and HDL cholesterol and triglycerides; use of insulin therapy and antihypertensive, statin, fibrate, and antiplatelet drugs; and history of current smoking and macrovascular disease. Plasma concentrations of TNFR1 and IMA were introduced into the model as categorical variables (tertiles). All analyses were performed in individuals without a baseline history of major LEAD (n = 1,290).